Articles tagged with Hormone Therapy
A six-month open-label study found that treatment with a 2% testosterone solution improved low sex drive and low energy symptoms in men with hypogonadism. The safety profile was consistent with previous trials, indicating that long-term treatment is safe and effective.
A new study analyzes breast tumors before and after hormone-reduction therapy, revealing the genetic complexity of these tumors and their varying responses to estrogen-deprivation treatments. The findings suggest that analyzing a single sample is insufficient for understanding how a patient should be treated.
Researchers at Brigham and Women's Hospital found that African-American men treated with hormone therapy had a 77% higher risk of death compared to non-African American men. The study analyzed over 7,000 patients and found that the increased mortality rate was not due to prostate cancer.
Researchers at UTA are studying how estrogen levels impact females' sensitivity to cocaine's rewarding effects and their risk of addiction. They found that estrogen activates messenger pathways in the dopamine reward system, making drugs more or less rewarding.
Researchers found that treating patients with a male hormone increased telomere length and improved hemoglobin mass. The study suggests a possible approach to combat diseases caused by telomerase deficiency.
A recent study published in Neurology found that hormone therapy has a negligible impact on verbal memory and mental skills in postmenopausal women, with or without early treatment. The research suggests that healthy women at any stage after menopause should not take estrogen to improve their cognitive abilities.
A large placebo-controlled study found that testosterone therapy significantly improved sexual interest and function in older men with low libido and low testosterone levels. The study, the largest of its kind, showed consistent improvement in most types of sexual activity among those who received testosterone therapy.
A five-year federal grant will discover progesterone-like compounds from commonly consumed botanicals and their role in women's health. The research aims to improve safety and inform decisions on self-medicating with botanicals.
A UCLA-led study estimates that nearly 28,500 deaths in the US could be prevented annually through use of a new FDA-approved class of cardiovascular medication. The therapy helps reduce mortality in patients diagnosed with heart failure and reduced ejection fraction by enhancing protective hormonal systems.
A review of 60 studies found that plant-based therapies like phytoestrogens and herbal remedies may improve menopausal symptoms, such as hot flashes and vaginal dryness. However, the evidence is limited by quality and more rigorous studies are needed to confirm these findings.
A consensus conference of international experts found testosterone therapy to be effective in treating low testosterone levels, regardless of underlying origin. The panel rejected concerns about increased cardiovascular risk, stating that the evidence suggests potential cardio-protective effects.
Biologists from UNIGE reveal a mechanism of resistance to the anti-estrogenic drug tamoxifen, identifying eight factors that enable breast cancer cells to become refractory to treatment. The researchers suggest various approaches for developing new therapies targeting these factors.
Researchers found that inhibiting the p110α PI3K isoform is sufficient to block tumor growth and metastasis in a mice model of pancreatic neuroendocrine tumors. The study demonstrates promise for a new targeted therapy, with potential benefits including reduced toxicity compared to generic inhibitors.
A new study by Drexel University found that making art can significantly reduce stress-related hormones in the body, with 75% of participants experiencing a decrease. The study also found no correlation between past art experience and cortisol levels, suggesting that anyone can benefit from creative expression.
A team of researchers has successfully grown functional pituitary tissue from human stem cells that can release hormones important for growth, reproductive functions, and stress response. The study's findings hold promise for a more permanent therapeutic option for patients with hypopituitarism.
A new study published at EULAR 2016 found that oestrogens significantly slow down fibrosis in experimental models representative of systemic sclerosis. This could lead to the development of potential hormone therapies for this difficult-to-treat condition.
A U of T Engineering team has designed a simpler way to keep therapeutic proteins localized for long periods. They found that proteins can be released over several weeks without encapsulation by controlling electrostatic interactions between proteins and nanoparticles.
Researchers found that hormone PYY improves insulin and glucagon secretion in rats with type 2 diabetes. Gastric bypass surgery has been shown to improve diabetes symptoms, and this study suggests a potential link between the two.
Researchers discovered a new factor in seizure escalation: estrogen synthesis in the brain. Aromatase inhibitors showed promise in suppressing seizures without negative side effects, promising a novel therapeutic approach.
A longitudinal Nordic study shows that combining hormone therapy with local radiotherapy halves the risk of death from prostate cancer 15 years after diagnosis. Researchers found that treatments with radiotherapy reduced mortality rates from 34 to 17 percent.
A large analysis of medical records in Sweden found that men taking testosterone therapy for over a year had no increased risk of prostate cancer and, in fact, had their risk reduced by 50 percent. The study's findings suggest that balancing testosterone levels within a normal range may be key to protecting against aggressive disease.
A recent study found that testosterone therapy improved erectile function and intercourse satisfaction in men with severe hypogonadism, a condition often associated with type 2 diabetes. The study suggests that trials of testosterone therapy should last at least 6 months for optimal results.
Researchers have identified how low testosterone raises diabetes risk by impairing insulin regulation in the pancreas. Testosterone triggers key signaling mechanisms that produce insulin, and its absence leads to glucose intolerance.
The Women's Health Initiative has received the AACR Team Science Award for its pioneering research on hormone therapy and nutrition in cancer risk prevention. The program, which involved over 161,000 postmenopausal women, found significant increases in heart disease, stroke, and breast cancer risks with combination hormone therapy.
Research highlights the impact of dietary habits on male reproductive potential, with obesity found to promote hormonal dysfunction and affect fertility. The study emphasizes the need for policymakers and media attention to address this growing health issue.
A large-scale population-based study found that older men using testosterone therapy had lower rates of hospital readmissions compared to non-users. The study, published in Mayo Clinic Proceedings, analyzed data from over 6,000 men and showed a 9.8% rate of 30-day hospital readmissions among testosterone users versus 13% for non-users.
Testosterone therapy appears to be safe in the short term, with benefits including improved well-being, decreased gender dysphoria, and reduced breast cancer risk. However, potential undesired effects include acne, alopecia, and increased blood pressure.
A new study finds a significant association between androgen deprivation therapy and depression in patients with localized prostate cancer. Patients treated with hormone therapy experienced higher incidences of depression, with risks increasing with treatment duration.
Researchers have identified new molecular targets for treating musculoskeletal diseases such as sarcopenia and osteoporosis. Several promising treatment options are expected to be available in the near future.
A new study from Intermountain Medical Center Heart Institute shows that testosterone supplementation reduced major adverse cardiovascular events in elderly men with low testosterone levels and pre-existing coronary artery disease. The study found that patients receiving testosterone therapy had a lower risk of heart attacks, strokes, ...
Researchers at Northwestern University developed an ovary bioprosthesis implant using a 3D printer, allowing mice to bear live young after ovary removal. The technology aims to restore fertility and hormone function in women affected by cancer treatments or born with reduced ovarian function.
A new study found that estrogen replacement therapy improves verbal memory and cognitive flexibility in young female athletes with amenorrhea. The study showed significant improvements in both immediate recall of words and ability to switch between tasks, even when controlling for age and pre-treatment test scores.
A new study found that AMH levels are related to high testosterone secretion and abdominal adiposity, making it a possible surrogate for ovarian antral follicle number. Additionally, AMH levels were correlated with age and body mass index, indicating its potential as a biomarker for PCOS diagnosis in obese adolescent girls.
Researchers at Northwestern University developed a prosthetic ovary implant using 3D printing technology that restored fertility in mice. The bioprosthesis was made from gelatin and supported hormone-producing cells and immature egg cells, enabling oocyte growth and ovulation.
The Endocrine Society recommends against using compounded hormone medications, citing potential risks and side effects. FDA-approved treatments are considered safer and more effective for treating hormone disorders.
A Swedish population study found that estrogen-only therapy carries a lower risk of blood clots than combined estrogen-progestogen therapy. Transdermal estrogen and vaginal estrogen also show no significantly increased risk of blood clots.
A leading doctor argues that doctors are failing to treat people with gender dysphoria, with one in five GPs refusing hormone prescriptions. The need for treatment is high, with a combined waiting list of over 5,000 people worldwide.
Researchers found that taking hormone therapy within six years of menopause can slow the buildup of plaque in arteries and prevent heart disease. The study suggests that timing is crucial for the effectiveness of hormone therapy in preventing atherosclerosis progression.
A new treatment combination of palbociclib and fulvestrant has been shown to significantly extend progression-free survival in women with stage-4 breast cancer. The study found that patients treated with the combination experienced a prolonged disease control, which may translate to improved survival.
A widely recommended therapy to prevent premature birth has been found to be ineffective in preventing early delivery. The treatment, which involves administering the hormone progesterone, does not appear to pose any risk to mothers or babies, but its effectiveness in reducing premature births is zero.
Researchers found testosterone treatment improved all aspects of sexual function, including sexual activity and desire, in men with low testosterone levels. However, the study did not confirm earlier concerns about cardiovascular safety.
A large nationwide study found that testosterone treatment improved sexual desire and function, as well as mood and depressive symptoms, in men with low testosterone levels. The treatment also showed no significant increase in cardiovascular issues.
Researchers found testosterone treatment benefits older men with low testosterone levels, improving sexual function, walking ability, and mood. The treatment also had no significant impact on energy but reduced depressive symptoms.
The Testosterone Trials found that testosterone treatment increased blood testosterone levels and improved all aspects of sexual function, including desire and ability to get an erection. The treatment also showed benefits in mood and depressive symptoms, but not energy or distance walked.
Researchers at Yale University found that testosterone therapy significantly improved sexual function, including sexual activity, desire, and erectile function, in men over age 65. Additionally, testosterone treatment showed modest benefits in terms of improved mood and fewer depressive symptoms.
The TTrials study reveals that testosterone treatment improves sexual function, including increased sexual activity and desire, as well as walking ability and mood. However, the treatment did not significantly improve energy or cognitive function, and its risks remain unclear.
Long-term use of liraglutide can lead to a gradual exhaustion of insulin-producing beta cells, reducing their secretion of insulin. This study using humanized mice suggests the need for caution when prescribing long-term GLP-1 analogues.
A systematic review of hormone therapy's effects on transgender individuals found significant improvements in mental health status and quality of life after as little as 3-6 months of treatment. Researchers suggest that increased access to hormone therapy could help eliminate or reduce depression and anxiety in this population.
Emerging vascular risk factors like inflammatory markers, endothelial dysfunction, and lipid disorders show gender differences. Women tend to have higher CVD risk than men, except for tumor necrosis factor-alpha and homocysteine levels.
A study by Massachusetts General Hospital found that proton therapy is as effective as standard radiotherapy for treating medulloblastoma, a common malignant brain tumor in children, while causing fewer long-term side effects. Proton therapy reduced hearing loss and cognitive deficits compared to photon radiotherapy.
A new study suggests that proton beam therapy is as safe and effective as conventional radiotherapy in treating childhood brain cancer, medulloblastoma. The treatment may also reduce the risk of long-term side effects such as hearing loss and endocrine problems.
The Lupus Research Institute has awarded 12 novel research grants to investigate the link between bacteria and lupus, as well as innovative approaches to treating the disease. The grants aim to develop new treatments and potentially prevent lupus through cutting-edge research.
A recent study by Johns Hopkins Bloomberg School of Public Health suggests that estrogen may offer additional benefits to hormone replacement therapy or infertility treatment. The research found that estrogen dramatically reduced the amount of flu virus that replicated in infected cells from women, but not from men.
The Endocrine Society recommends treating severe primary adrenal insufficiency symptoms immediately, even if a diagnosis is not confirmed. Patients should undergo diagnostic testing to rule out the condition and receive glucocorticoid replacement therapy to maintain cortisol levels.
In a phase III trial, DHEA showed significant improvements in vaginal discomfort after menopause, reducing pain with sex by 0.36 points and improving vaginal dryness by 0.27 points compared to a placebo. The treatment also led to increased superficial cells and decreased parabasal cells, indicating improved vaginal health.
Researchers developed an antibody targeting a hormone in adipose tissue called aP2 to improve glucose regulation and reduce liver fat in obese mice. The study found that one of the antibodies effectively improved glucose regulation in two independent models of obesity, with beneficial reductions in liver fat.
Scientists found that brief exposure to 'asynchrony' using a pacemaker can reverse cellular damage, fix damaged motor proteins in the heart muscle, and boost the heart's response to hormones like adrenaline. The therapy uses alternating electrical shocks to push the heart into normal synchronization for part of each day.
A study published in the Journal of the American Society of Hematology found that women on blood thinners can take hormone-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. The study analyzed data from 1,888 women and showed similar incidence rates of blood clots and a...
The number of compounded hormone therapy prescriptions has reached 26-33 million a year, with sales expected to continue growing despite potential risks. The lack of clinical data and quality control concerns over these products is alarming.
The PALOMA3 trial confirms the efficacy of combining palbociclib with fulvestrant in Asian patients with hormone receptor-positive, HER2-negative advanced breast cancer. The combination shows positive results in progression-free survival for postmenopausal women, while a longer follow-up is needed to confirm overall survival.